Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q4 EPS of ($1.35), $0.37 worse than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.